United Homes Group stock plunges after Nikki Haley, directors resign
Ocular Therapeutix (NASDAQ:OCUL), whose shares have surged 86% over the past six months and currently commands a market capitalization of $2 billion, reported that Chief Legal Officer Todd Anderman sold 11,132 shares of common stock on October 8, 2025, for approximately $137,368. The shares were sold at a weighted average price ranging from $12.00 to $12.5114.
The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission. Following the sale, Anderman directly owns 87,568 shares of Ocular Therapeutix.
The sale was executed pursuant to a pre-arranged automatic sale instruction adopted on October 7, 2024, to cover tax withholding obligations related to the vesting of restricted stock units. The company maintains a strong balance sheet, with cash holdings exceeding debt and liquid assets surpassing short-term obligations. For deeper insights into insider trading patterns and 11 additional ProTips, visit InvestingPro.
In other recent news, Ocular Therapeutix has announced a significant update regarding its AXPAXLI clinical trials. The company is conducting two Phase 3 trials for the treatment of wet age-related macular degeneration, with the SOL-1 trial having successfully randomized 344 subjects. The primary endpoint focuses on maintaining visual acuity, and no new safety concerns have been reported. Additionally, Ocular Therapeutix has priced a common stock offering, raising approximately $475 million in gross proceeds, with the offering expected to close by October 1, 2025. In terms of analyst activity, Piper Sandler raised its price target for Ocular Therapeutix to $31, citing optimism about the company’s clinical trials. H.C. Wainwright also increased its price target to $19, following the FDA’s grant of a Special Protocol Assessment for the treatment of non-proliferative diabetic retinopathy. Citizens JMP raised its target to $29, highlighting the company’s innovation capabilities. These developments reflect growing confidence in Ocular Therapeutix’s ongoing projects and financial strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.